HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS - Free Report) in a report published on Tuesday, Benzinga reports. The brokerage currently has a $221.00 price target on the stock.
Several other analysts have also recently commented on KRYS. Citigroup reissued a "neutral" rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. William Blair raised Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Finally, Evercore ISI raised their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $197.00.
Check Out Our Latest Research Report on KRYS
Krystal Biotech Stock Performance
Shares of NASDAQ:KRYS traded up $3.56 during mid-day trading on Tuesday, hitting $174.41. The stock had a trading volume of 245,166 shares, compared to its average volume of 329,234. The company's 50 day moving average is $181.81 and its 200-day moving average is $180.23. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34. The company has a market cap of $5.01 billion, a PE ratio of 98.54 and a beta of 0.82.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. During the same period in the previous year, the company earned ($0.67) earnings per share. The company's revenue was up 879.9% compared to the same quarter last year. On average, equities research analysts predict that Krystal Biotech will post 2.88 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 14.10% of the stock is owned by corporate insiders.
Institutional Trading of Krystal Biotech
Several hedge funds have recently bought and sold shares of the stock. EFG Asset Management North America Corp. grew its holdings in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock worth $2,308,000 after purchasing an additional 60 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock worth $173,000 after acquiring an additional 94 shares in the last quarter. Arizona State Retirement System lifted its position in Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock valued at $945,000 after acquiring an additional 108 shares during the last quarter. Finally, Fiera Capital Corp boosted its stake in Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock valued at $2,976,000 after acquiring an additional 130 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Articles
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
